JumpCan continues to strengthen its market presence in core therapeutic areas where it has established advantages, including pediatrics, gastroenterology, and autoimmune diseases. In response to population aging, the company is also actively expanding into strategic new areas such as cardiovascular and other chronic disease management.
We continue to increase R&D investment and attract outstanding scientific talent. Through independent innovation, licensing-in, collaborative development, investment incubation, and other models, we are further enriching our R&D pipeline to deliver more high-quality innovative medicines and help protect life and health.